Declining Incidence of Systolic Left Ventricular Dysfunction in Human Immunodeficiency Virus–Infected Individuals Treated With Highly Active Antiretroviral Therapy

• Published in: The American journal of cardiology Vol. 117; no. 7; pp. 1194 - 1195
• Main Authors: Fisher, Stacy D., Starc, Thomas J., Guerra, Vitor, Williams, Paige L., Wilkinson, James D., Lipshultz, Steven E.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2016; Elsevier Limited
• Subjects: Acquired immune deficiency syndrome; AIDS; Antiretroviral drugs; Antiretroviral Therapy, Highly Active; Heart attacks; HIV; HIV Infections - complications; HIV Infections - drug therapy; Human immunodeficiency virus; Humans; Incidence; Mortality; Ventricular Dysfunction, Left - epidemiology
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2016.01.008

[...]the risk of premature cardiovascular disease has been associated with specific antiretroviral therapies.7 Nucleoside reverse transcriptase inhibitors have been associated with mitochondrial toxicity,8 although a study in both HIV-infected and HIV-exposed uninfected infants whose HIV-infected mothers received zidovudine during pregnancy to prevent transmission showed no adverse cardiac effects in the first 10 to 14 months of life.9 Protease inhibitors have been implicated in adversely affecting cardiac function and atherogenic risk in both adults and children.10-12 Protease inhibitor-containing regimens specifically have been associated with an increase in LV mass and with diastolic dysfunction in adults.13 The Adolescent Master Protocol (AMP) of the National Institutes of Health-funded Pediatric HIV/AIDS Cohort Study is a prospective cohort conducted at 14 US sites, designed to evaluate the impact of HIV infection and antiretroviral therapy on the development of children and adolescents with perinatal HIV.